新型胰岛素促分泌剂rExendin-4体内药效学评价

Pharmacodynamic evaluation of a new insulinotropic agent rExendin-4 in vivo

目的考察基因工程肽类rExendin-4(降血糖药)在正常ICR小鼠体内的药效学作用特征。方法选用正常ICR小鼠,考察rExendin-4对动物空腹血糖、糖负荷后血糖的变化、血清胰岛素水平以及胃肠蠕动的影响。结果 rEx-end in-4可以降低血糖,抑制糖负荷后血糖的升高;其促胰岛素分泌作用依赖于血糖升高的刺激,不伴随胰岛素引起的低血糖效应。结论 rExendin-4可安全有效的降低血糖,对糖尿病的防治具有良好的应用前景。

Objective To identify the pharmacodynamics of a new genetic engineering peptide, rExendin -4, in normal ICR mice. Methods In normal ICR mice, observe rExendin -4＇s effects on blood glucose and serum insulin level, as well as blood glucose fluctuation after oral glucose load. Results The rExendin -4 shows benefitial blood glucose normalization, which dependents on the higher blood glucose stimulation and without hypoglycemia induced by insulin. It means to be a new insu- linotropic agent. Conclusion The rExendin -4 can effectively and safely achieve the ideal therapy target for type 2 diabetes mellltus with much less side effects such as hypoglycemia and weight gain, and possess favorable applieation perspective.